Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2021-04-12 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the participation of Medexus Pharmaceuticals' CEO and CFO in upcoming investor conferences in April 2021. It provides details about the conferences and contact information but does not contain any financial statements, detailed financial data, or regulatory filings. The document length is 3319 characters, which is relatively short and does not include any report or financial results. It is an announcement related to investor presentations but is not the presentation itself. Therefore, it fits best under the category of Investor Presentation announcements or related updates. However, since it is an announcement of participation rather than the presentation content, and given the available categories, the closest fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories specifically.
2021-04-12 English
Other securityholders documents - English.pdf
Regulatory Filings
2021-04-01 English
Other securityholders documents - English.pdf
Regulatory Filings
2021-04-01 English
News release - English.pdf
Director's Dealing Classification · 95% confidence The document is a press release announcing that all non-executive directors of Medexus Pharmaceuticals have elected to receive restricted share units (RSUs) in lieu of cash fees for the 2021 calendar year. It discusses director compensation choices and equity incentive plans but does not contain financial statements, detailed financial results, or regulatory filings. The document length is 3046 characters, which is relatively short and more consistent with an announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a Board/Management Information announcement about changes in board or management personnel, but rather about director compensation method. The closest fitting category is Director's Dealing (DIRS), which covers reports of personal share transactions or share-based compensation by directors. Therefore, the document is best classified as DIRS with high confidence.
2021-03-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended December 31, 2020. The document is a certification letter rather than the actual interim financial report or MD&A. It explicitly states it is a certificate and does not contain substantive financial data or analysis itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is short (3000 characters), consistent with a certification letter rather than a full report. Therefore, the correct classification is Regulatory Filings (RNS).
2021-03-01 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended December 31, 2020. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but does not include the report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (2996 characters), consistent with a certification letter rather than a full report.
2021-03-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.